[go: up one dir, main page]

EP3720474A4 - Products and methods for assessing and increasing klotho protein levels - Google Patents

Products and methods for assessing and increasing klotho protein levels Download PDF

Info

Publication number
EP3720474A4
EP3720474A4 EP18885984.7A EP18885984A EP3720474A4 EP 3720474 A4 EP3720474 A4 EP 3720474A4 EP 18885984 A EP18885984 A EP 18885984A EP 3720474 A4 EP3720474 A4 EP 3720474A4
Authority
EP
European Patent Office
Prior art keywords
assessing
products
methods
protein levels
klotho protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP18885984.7A
Other languages
German (de)
French (fr)
Other versions
EP3720474A2 (en
Inventor
Joseph F. Tarsio
Dinesh RATURI
William Ian Ramage
James R. PLANTE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Klotho Therapeutics Inc
Original Assignee
Klotho Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US16/208,552 external-priority patent/US20190169593A1/en
Application filed by Klotho Therapeutics Inc filed Critical Klotho Therapeutics Inc
Publication of EP3720474A2 publication Critical patent/EP3720474A2/en
Publication of EP3720474A4 publication Critical patent/EP3720474A4/en
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/96Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/47Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/24Hydrolases (3) acting on glycosyl compounds (3.2)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/24Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y301/00Hydrolases acting on ester bonds (3.1)
    • C12Y301/01Carboxylic ester hydrolases (3.1.1)
    • C12Y301/010316-Phosphogluconolactonase (3.1.1.31)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y302/00Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01031Beta-glucuronidase (3.2.1.31)
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90Enzymes; Proenzymes
    • G01N2333/914Hydrolases (3)
    • G01N2333/924Hydrolases (3) acting on glycosyl compounds (3.2)
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2560/00Chemical aspects of mass spectrometric analysis of biological material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
EP18885984.7A 2017-12-06 2018-12-06 Products and methods for assessing and increasing klotho protein levels Pending EP3720474A4 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762595567P 2017-12-06 2017-12-06
US201862666868P 2018-05-04 2018-05-04
US201862692195P 2018-06-29 2018-06-29
US16/208,552 US20190169593A1 (en) 2016-06-02 2018-12-03 Products and methods for assessing and increasing klotho protein levels
PCT/US2018/064333 WO2019113373A2 (en) 2017-12-06 2018-12-06 Products and methods for assessing and increasing klotho protein levels

Publications (2)

Publication Number Publication Date
EP3720474A2 EP3720474A2 (en) 2020-10-14
EP3720474A4 true EP3720474A4 (en) 2021-12-29

Family

ID=66750330

Family Applications (1)

Application Number Title Priority Date Filing Date
EP18885984.7A Pending EP3720474A4 (en) 2017-12-06 2018-12-06 Products and methods for assessing and increasing klotho protein levels

Country Status (6)

Country Link
EP (1) EP3720474A4 (en)
JP (2) JP7290340B2 (en)
KR (1) KR102831784B1 (en)
AU (2) AU2018378802B2 (en)
CA (1) CA3101100A1 (en)
WO (1) WO2019113373A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020160617A1 (en) * 2019-02-05 2020-08-13 Helium 3 Biotech Pty Ltd A membrane protein expression and distribution modulating composition and method of use thereof
CN111184728B (en) * 2020-02-20 2023-04-04 上海市儿童医院 Application of trehalose in nephrotic syndrome
CN112114075B (en) * 2020-09-17 2022-12-09 哈尔滨珍宝制药有限公司 Construction method and quality evaluation method of notopterygium root Shengshi Shang Zhiwen map
CN116211898A (en) * 2020-11-26 2023-06-06 内蒙古伊利实业集团股份有限公司 Bifidobacterium lactis BL-99 regulating sleep and its application
CN114441696A (en) * 2021-12-22 2022-05-06 南京格亚医药科技有限公司 A kind of detection method of eribulin mesylate key intermediate
KR102802882B1 (en) * 2022-04-05 2025-05-08 한국과학기술연구원 Dilution solution for measuring free steroid in blood and method for measuring steroid using the same
EP4434534A1 (en) 2023-03-22 2024-09-25 ADvantage Therapeutics, Inc. Klotho mrna
WO2025205534A1 (en) * 2024-03-25 2025-10-02 積水メディカル株式会社 Immunoassay method, accuracy management method, standard sample, and immunoassay reagent

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090192087A1 (en) * 2008-01-28 2009-07-30 Novartis Ag Methods and Compositions Using Klotho-FGF Fusion Polypeptides
WO2012018638A2 (en) * 2010-07-26 2012-02-09 Biomatrica, Inc. Compositions for stabilizing dna, rna and proteins in blood and other biological samples during shipping and storage at ambient temperatures
WO2016015162A1 (en) * 2014-07-31 2016-02-04 The Governing Council Of The University Of Toronto ANTIBODIES WITH HIGH AFFINITY FOR αKLOTHO

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4313927A (en) * 1979-10-19 1982-02-02 Ames-Yissum Ltd. Immunoassay method for detecting viral antibodies in whole blood samples
DE69127383T2 (en) * 1990-01-19 1998-03-05 Mina Ltd Device and method for examining blood and for fingerprint identification
US20030109067A1 (en) * 2001-12-06 2003-06-12 Immunetech, Inc. Homogeneous immunoassays for multiple allergens
DE102005003789A1 (en) * 2005-01-19 2006-07-27 Roche Diagnostics Gmbh Test unit for one-time examinations of a body fluid
US7467065B2 (en) * 2005-05-02 2008-12-16 Home Diagnostics, Inc. Computer interface for diagnostic meter
US7575876B2 (en) * 2005-10-27 2009-08-18 The University Of Washington Biomarkers for neurodegenerative disorders
JP5201822B2 (en) * 2006-12-11 2013-06-05 アボット・ラボラトリーズ Immunological assay for gastrin releasing peptide precursor
US10555963B2 (en) * 2007-05-08 2020-02-11 Tel Hashomer Medical Research Infrastructure And Services Ltd. Klotho protein and related compounds for the treatment and diagnosis of cancer
BRPI0815416A2 (en) * 2007-08-15 2014-10-21 Amunix Inc COMPOSITIONS AND METHODS FOR MODIFYING PROPERTIES OF BIOLOGICALLY ACTIVE POLYPEPTIDES
US8728744B2 (en) * 2007-10-26 2014-05-20 The Regents Of The University Of California Salivary protein biomarkers for human oral cancer
WO2011050110A1 (en) * 2009-10-20 2011-04-28 Boston Microfluidics Methods and systems to collect and prepare samples, to implement, initiate and perform assays, and to control and manage fluid flow
EP2512500A1 (en) * 2009-12-16 2012-10-24 Eli Lilly and Company Therapeutic uses of soluble alpha-klotho
CN107209095A (en) * 2014-11-28 2017-09-26 奇普凯尔公司 Multiple pearl array is determined
EP3551212A4 (en) * 2016-11-22 2020-11-04 Klotho Therapeutics, Inc. NOVEL RECOMBINANT KLOTHO PROTEINS AND COMPOSITIONS AND PROCESSES THEREOF

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090192087A1 (en) * 2008-01-28 2009-07-30 Novartis Ag Methods and Compositions Using Klotho-FGF Fusion Polypeptides
WO2012018638A2 (en) * 2010-07-26 2012-02-09 Biomatrica, Inc. Compositions for stabilizing dna, rna and proteins in blood and other biological samples during shipping and storage at ambient temperatures
WO2016015162A1 (en) * 2014-07-31 2016-02-04 The Governing Council Of The University Of Toronto ANTIBODIES WITH HIGH AFFINITY FOR αKLOTHO

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
MICHELLE SHARDELL ET AL: "Plasma Klotho and Frailty in Older Adults: Findings From the InCHIANTI Study", JOURNALS OF GERONTOLOGY, SERIES A, BIOLOGICAL SCIENCES ANDMEDICAL SCIENCES, vol. 00, 19 October 2017 (2017-10-19), US, pages 1 - 6, XP055521719, ISSN: 1079-5006, DOI: 10.1093/gerona/glx202 *
ROTONDI SILVERIO ET AL: "Soluble [alpha] -Klotho Serum Levels in Chronic Kidney Disease", INTERNATIONAL JOURNAL OF ENDOCRINOLOGY, vol. 2015, 1 January 2015 (2015-01-01), US, pages 1 - 8, XP055832442, ISSN: 1687-8337, Retrieved from the Internet <URL:http://downloads.hindawi.com/journals/ije/2015/872193.pdf> [retrieved on 20210816], DOI: 10.1155/2015/872193 *

Also Published As

Publication number Publication date
AU2018378802B2 (en) 2024-08-15
AU2018378802A1 (en) 2020-07-23
EP3720474A2 (en) 2020-10-14
WO2019113373A3 (en) 2019-09-26
CA3101100A1 (en) 2019-06-13
KR20200095538A (en) 2020-08-10
KR102831784B1 (en) 2025-07-09
JP2021508037A (en) 2021-02-25
AU2024259844A1 (en) 2024-11-28
JP7290340B2 (en) 2023-06-13
JP2023113737A (en) 2023-08-16
WO2019113373A2 (en) 2019-06-13

Similar Documents

Publication Publication Date Title
EP3720474A4 (en) Products and methods for assessing and increasing klotho protein levels
EP3244727A4 (en) Insecticidal proteins and methods for their use
KR101881739B1 (en) Apparatus and methods for modifying keratinous surfaces
EP3235830A4 (en) Interleukin 15 protein complex and use thereof
EP3147298A4 (en) Pd-l1 fusion protein and use thereof
IL278490A (en) Taste and flavor-modifier proteins
EP3142680A4 (en) Lpa-associated protein and rna expression
CA3247217A1 (en) Bis-octahydrophenanthrene carboxamides and protein conjugates thereof
PL3240436T3 (en) Composition containing chitin and digestible proteins
EP3290441A4 (en) RGMa BINDING PROTEIN AND USE THEREOF
EP3256163A4 (en) Methods and compositions for modulating lilr proteins
EP3226844A4 (en) Proteins and protein conjugates with increased hydrophobicity
EP3393586A4 (en) Bromodomain and extra-terminal protein inhibitor combination therapy
GB201710288D0 (en) Products and methods
GB201905674D0 (en) Aquafaba products and methods
GB2582521B (en) Preserved tissue products and related methods
EP3309167A4 (en) Small-molecule polypeptide zy4 and application thereof
EP3503516B8 (en) Capturing method and related products
EP3229595A4 (en) Reduction of milk glycans and their degradation products in the neonate gut
IL291284A (en) Systems and methods for protein expression
GB201802184D0 (en) Products and methods
EP3585798A4 (en) In vivo protein n-acylation
EP3241022A4 (en) Methods for protein and peptide reduction
EP3188826A4 (en) Systems and methods for assessing therapeutic proteins
GB2583732B (en) Methods and products

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20200619

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
RIC1 Information provided on ipc code assigned before grant

Ipc: G01N 33/68 20060101ALI20210819BHEP

Ipc: A61K 45/06 20060101ALI20210819BHEP

Ipc: G01N 33/573 20060101ALI20210819BHEP

Ipc: C12N 9/24 20060101ALI20210819BHEP

Ipc: A61P 13/12 20060101ALI20210819BHEP

Ipc: A61K 38/00 20060101AFI20210819BHEP

REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Free format text: PREVIOUS MAIN CLASS: A61K0038470000

Ipc: A61K0038000000

A4 Supplementary search report drawn up and despatched

Effective date: 20211125

RIC1 Information provided on ipc code assigned before grant

Ipc: G01N 33/68 20060101ALI20211119BHEP

Ipc: A61K 45/06 20060101ALI20211119BHEP

Ipc: G01N 33/573 20060101ALI20211119BHEP

Ipc: C12N 9/24 20060101ALI20211119BHEP

Ipc: A61P 13/12 20060101ALI20211119BHEP

Ipc: A61K 38/00 20060101AFI20211119BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20250409

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20250929